Reporters.io
John Pinching
PharmaTimes
Profile
Contacts
Recent Articles on Subject
1
John Pinching
PharmaTimes
Next-gen biopharma company.
La Jolla, California
biopharma
drugs
devices
Genome editing offers hope for genetic hearing loss
- 6 days ago
Amivantamab plus lazertinib shows survival benefit in lung cancer
- 6 days ago
Linda Härmark
- 7 days ago
Nouscom reveals promising results for lynch syndrome immunotherapy
- 7 days ago
Seth Benson
- 8 days ago
Kieron Hall
- 8 days ago
SECuRE trial pre-chemo participants experience PSA level drops
- 28 days ago
Rotherham NHS Foundation Trust enhances patient engagement
- 28 days ago
Bas Vorsteveld
- 30 days ago
Centauri therapeutics selects first ABX-01 clinical candidate
- 30 days ago
Professor Dr Uli Brödl
- about 1 month ago
Blood cancer patients face treatment access disparity
- about 1 month ago
Datapharm collaborates with VIDAL to improve medicines information access in France
- about 1 month ago
Brainomix partners with Medtronic to enhance stroke care
- about 1 month ago
Microbiotica unveils new data on MB097 at AACR IO meeting
- about 1 month ago
Mitazalimab shows promising survival rates in cancer study
- about 1 month ago
Cambridge scientists develop ‘super test’ for prostate cancer
- about 1 month ago
Bath researchers awarded Wellcome grant for psychotic disorder study
- about 1 month ago
Andembry treatment approved across Europe
- about 2 months ago
Illuccix therapy gets approval in the UK
- about 2 months ago
Amlenetug receives FDA Fast Track Designation
- about 2 months ago
Bimekizumab shows long-term efficacy in hidradenitis suppurativa
- about 2 months ago
Libtayo available in Scotland for cervical cancer patients
- about 2 months ago
Lynparza approved in Scotland for BRCA-mutated breast cancer patients
- about 2 months ago
Capgemini unveils AI breakthrough to boost bioeconomy
- about 2 months ago
Hemgenix shows efficacy among haemophilia B patients
- about 2 months ago
Qureight and Avalyn launch strategic partnership in pulmonary fibrosis
- about 2 months ago
FDA grants Orphan Drug Designation to Ariceum cancer therapy
- about 2 months ago
Rippon Ubhi
- about 2 months ago
Novartis secures MHRA authorisation for ribociclib
- about 2 months ago
Grifols collaborates with startup FcR Therapeutics to develop autoimmune therapies
- about 2 months ago
Aplagon secures EUR 7 million for APAC phase 2a trials
- about 2 months ago
CHMP recommends SC Rybrevant for EGFR-mutated NSCLC patients
- about 2 months ago
Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials
- 3 months ago
Actinogen boosts trial with Cambridge Cognition’s digital suite
- 3 months ago
Owlstone Medical announces $27 million USD first close in Series E financing round
- 3 months ago
Oxford Drug Design achieves in vivo validation for novel cancer treatment
- 3 months ago
Pheno Therapeutics granted trial authorisation for MS candidate
- 3 months ago
Grifols pioneers high-tech analysis of plasma bank to detect Parkinson’s disease
- 3 months ago
AI set to revolutionise pharmaceutical R&D says GlobalData
- 3 months ago
Gilead and LEO Pharma partner to develop oral STAT6 program
- 3 months ago
Cambridge Cognition highlights positive Cantab results
- 3 months ago
Angelini Ventures co-leads Series A financing in Neumirna Therapeutics
- 3 months ago
Novartis gene therapy set to enhance SMA treatment
- 3 months ago
Merck unveils new cyber-physical trust platform at CES 2025
- 3 months ago
New prostate cancer test cuts biopsies by 50% in US
- 3 months ago
Amgen’s lung cancer treatment gets conditional approval
- 3 months ago
NHS Confederation welcomes social care commission announcement
- 3 months ago
FDA approves Sequana Medical’s Alfapump for ascites treatment
- 3 months ago
EC approves Rybrevant with Lazcluze for advanced lung cancer
- 3 months ago
2
Urte Jakimaviciute
PharmaTimes
AI set to revolutionise pharmaceutical R&D says GlobalData
- 3 months ago
3
Christie Wong
PharmaTimes
Novartis gene therapy set to enhance SMA treatment
- 3 months ago